Murray Yule News Today

Study becomes the first-in-human clinical trial involving OMX-0407 in a specific patient group - News - PharmaTimes

Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from ... a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit.

03.02.2022 iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development | Chief Medical Officer | Dr. Murray Yule

Adcendo, a Copenhagen, Denmark-based biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers, raised EUR 51m (US$ 62m) in Series A financing. The round was led by Novo Seeds and Ysios Capital, with participation from RA Capital Management, HealthCap and Gilde Healthcare. As part of the financing, Jeroen Bakker, Principal at Novo Seeds, will join the Board. The company plans to use the funds to bring the lead program targeting the novel cancer target uPAR...

Share this article Share this article COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was in...

Novo Seeds co-leads Adcendos EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers - Novo Seeds played instrumental role in supporting Adcendo from inception - Plans to build a pipeline of ADCs directed at novel cancer targets COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today an investment in Adcendo, a Danish biotech company which is developing an...